Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBIT: 2020-2024

Historic EBIT for iSpecimen (ISPC) over the last 5 years, with Dec 2024 value amounting to -$12.7 million.

  • iSpecimen's EBIT fell 65.96% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.1 million, marking a year-over-year decrease of 24.31%. This contributed to the annual value of -$12.7 million for FY2024, which is 13.96% down from last year.
  • Per iSpecimen's latest filing, its EBIT stood at -$12.7 million for FY2024, which was down 13.96% from -$11.2 million recorded in FY2023.
  • iSpecimen's 5-year EBIT high stood at -$2.4 million for FY2020, and its period low was -$12.7 million during FY2024.
  • In the last 3 years, iSpecimen's EBIT had a median value of -$11.2 million in 2023 and averaged -$11.4 million.
  • Data for iSpecimen's EBIT shows a maximum YoY tumbled of 146.23% (in 2021) over the last 5 years.
  • iSpecimen's EBIT (Yearly) stood at -$2.4 million in 2020, then plummeted by 146.23% to -$5.9 million in 2021, then tumbled by 71.91% to -$10.2 million in 2022, then declined by 9.65% to -$11.2 million in 2023, then dropped by 13.96% to -$12.7 million in 2024.